What is Hyperion Therapeutics Change In Inventory?
Hyperion Therapeutics's change in inventory for the quarter that ended in Mar. 2015 was €-0.9 Mil. It means Hyperion Therapeutics's inventory
increased by €0.9 Mil
from Dec. 2014 to Mar. 2015 .
Hyperion Therapeutics's change in inventory for the fiscal year that ended in Dec. 2014 was €-1.1 Mil. It means Hyperion Therapeutics's inventory
increased by €1.1 Mil
from Dec. 2013 to Dec. 2014 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Hyperion Therapeutics's Days Inventory for the quarter that ended in Mar. 2015 was 114.93.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Hyperion Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2015 was 0.79.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hyperion Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2015 was 0.15.
Hyperion Therapeutics Change In Inventory Historical Data
The historical data trend for Hyperion Therapeutics's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyperion Therapeutics Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyperion Therapeutics (FRA:0HY) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Hyperion Therapeutics's Days Inventory for the quarter that ended in is calculated as:
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Hyperion Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyperion Therapeutics Change In Inventory Related Terms
Thank you for viewing the detailed overview of Hyperion Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:0HY has been successfully added to your 